Minimal-change disease in adolescents and adults: epidemiology and therapeutic response

被引:21
|
作者
Keskar, Vaibhav [1 ,2 ]
Jamale, Tukaram Ekanath [1 ,2 ]
Jeevanna, Kulkarni Manjunath [3 ]
Jagadish, Pradeep Kiggal [3 ]
Fernandes, Gwendolyn [4 ]
Hase, Niwrutti [1 ,2 ]
机构
[1] Seth GS Med Coll, Dept Nephrol, Bombay, Maharashtra, India
[2] King Edward Mem Hosp, Bombay, Maharashtra, India
[3] Grant Med Coll, Nephrol, Bombay, Maharashtra, India
[4] Seth GS Med Coll, Pathol, Bombay, Maharashtra, India
来源
CLINICAL KIDNEY JOURNAL | 2013年 / 6卷 / 05期
关键词
minimal-change disease in adults; nephrotic syndrome; treatment outcomes;
D O I
10.1093/ckj/sft063
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Epidemiology of minimal-change disease (MCD) in adults differs from that in children and is not studied well in Indian population. Methods. We retrospectively studied the records of 61 adult patients with MCD to assess clinical, laboratory and histopathological features, and to evaluate the response to treatment, course and complications of the disease and therapy. Results. The male to female ratio was 1.17:1. Mean age was 30.46 years. Of the total, 6.55% had hypertension; 13.11% had microhaematuria. After initial treatment with steroids, 68.85% had complete remission (CR) and 13.1% had partial remission (PR). Twelve of 14 (85.71%) steroidresistant cases had CR or PR after alternative immunosuppression with cyclophosphamide, or mycophenolate mofetil. Of all patients, 44.2% had at least one relapse; 8.19% were frequently relapsing and 26.22% were steroid dependent. After a mean follow-up of 149.9 weeks, 38 (61.29%) patients were in CR and 16 (26.22%) in PR with a mean proteinuria of 1.28 g/day, 3 being treated for relapse. Mean serum creatinine was 89.28 ae mol/L (1.01 mg/dL). Fourteen (22.95%) had acute kidney injury (AKI). All but two recovered completely. Conclusions. This single-centre study with a medium-term follow-up shows that majority of patients respond to steroids or alternative immunosuppressants. AKI is common and may not be completely reversible in some cases.
引用
收藏
页码:469 / 472
页数:4
相关论文
共 50 条
  • [31] Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
    Kannan, Lakshmi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [32] Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
    Dado, David
    Parikh, Samir
    Ayoub, Isabelle
    Rovin, Brad
    Nadasdy, Tibor
    Hebert, Lee
    CLINICAL NEPHROLOGY, 2018, 89 (05) : 376 - 380
  • [33] Yellow nail syndrome accompanied by minimal-change nephrotic syndrome: A case report
    Zhang, Ya-Nan
    Wang, Mei-Hua
    Yu, Wen-Cheng
    Cheng, Wei
    Cong, Jin-Peng
    Huang, Xue-Peng
    Wang, Fang-Fang
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (15) : 4949 - 4956
  • [34] Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy
    Janardan, Jyotsna
    Ooi, Khai
    Menahem, Solomon
    CLINICAL KIDNEY JOURNAL, 2014, 7 (03): : 293 - 295
  • [35] Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis
    Siligato, Rossella
    Cernaro, Valeria
    Nardi, Chiara
    De Gregorio, Francesca
    Gembillo, Guido
    Costantino, Giuseppe
    Conti, Giovanni
    Buemi, Michele
    Santoro, Domenico
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (11) : 839 - 879
  • [36] Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis
    Fernandez-Juarez, Gema
    Villacorta, Javier
    Ruiz-Roso, Gloria
    Panizo, Nayara
    Martinez-Marin, Isabel
    Marco, Helena
    Arrizabalaga, Pilar
    Diaz, Montserrat
    Perez-Gomez, Vanessa
    Vaca, Marco
    Rodriguez, Eva
    Cobelo, Carmen
    Fernandez, Loreto
    Avila, Ana
    Praga, Manuel
    Quereda, Carlos
    Ortiz, Alberto
    CLINICAL KIDNEY JOURNAL, 2016, 9 (03): : 381 - 386
  • [37] Emerging Minimal-change Nephrotic Syndrome in a Patient with Chronic Mesangial Proliferative Lupus Nephritis
    Deji, Naoko
    Sugimoto, Toshiro
    Kanasaki, Masami
    Aoyama, Masahiro
    Tanaka, Yuki
    Sakaguchi, Masayoshi
    Nishio, Yoshihiko
    Uzu, Takashi
    Kashiwagi, Atsunori
    INTERNAL MEDICINE, 2007, 46 (13) : 991 - 995
  • [38] Minimal change disease in graft versus host disease: a podocyte response to the graft?
    Huskey, Janna
    Rivard, Chris
    Myint, Han
    Lucia, Scott
    Smith, Maxwell
    Shimada, Michiko
    Ishimoto, Takuji
    Araya, Carlos
    Garin, Eduardo H.
    Johnson, Richard J.
    CLINICAL NEPHROLOGY, 2013, 80 (06) : 469 - 473
  • [39] Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
    Ren, Hong
    Lin, Li
    Shen, Pingyan
    Li, Xiao
    Xie, Jingyuan
    Pan, Xiaoxia
    Zhang, Wen
    Chen, Nan
    ONCOTARGET, 2017, 8 (55): : 93438 - 93443
  • [40] Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease
    Lionaki, Sophia
    Mantios, Evangelos
    Tsoumbou, Ioanna
    Marinaki, Smaragdi
    Makris, George
    Liapis, George
    Vergandis, Chrysovalantis
    Boletis, Ioannis
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)